Background/Aim: The surgical treatment of patients with bone metastasis of the extremities poses a set of unique challenges. We aimed to highlight common hazards when treating pathological fractures as well as hazards surrounding assumptions on metastatic status and life expectancy. Materials and Methods: This systematic literature review includes studies published from January 1, 1985 to May 7, 2021. Published articles were surveyed using PubMed. Of 99 studies, 32 original articles were found to meet the inclusion criteria. The PRISMA guidelines were used to select articles. Results: Current literature reports a variety of common pitfalls. In order to avoid pitfalls, it is essential to secure the diagnosis. Furthermore, life expectancy must be given consideration when planning surgical therapy. In addition, a well-functioning multidisciplinary team is needed to coordinate further options such as radiation or embolization. Conclusion: Despite the fact that the surgical principles for treating bone metastases of the extremities are often to the point, incorporating all the nuances of treatment is a meticulous procedure.A pitfall is an imperceptible hazard that often produces unforeseen difficulties and an unwanted result (1). Treating patients with metastatic disease means circumnavigating numerous potential pitfalls, many of which stem from the physician's bias when treating patients with "palliative" intent (1). In some cases, metastatic cancer of the bone requires consideration similar to primary sarcomas of the bone, while in other cases the palliative aims are obvious (1). The literature reports that approximately four million people experience bone pain from a malignant disease (2), with metastatic bone pain being one of the major complaints (2, 3). Additionally, bone metastases are a leading cause of comorbidity, characterized by pain, pathological fractures (impending and complete), impaired mobility, and potential neurological compromise (4).The spread of malignant cells from the primary tumor to other sites proceeds in a number of highly selective steps known as the metastatic cascade (5). Only 0.02% of malignant cells that enter the bloodstream are estimated to result in clinically detectable metastases (6). Histopathologically, the metastatic cascade commences when malignant cells are released by the primary tumor (5, 7). These cells subsequently invade healthy tissue and pass into the bloodstream by traversing the basal membrane of blood vessels or lymphatics (5, 7). The malignant cells leave the vessels and settle in a new organ away from the primary tumor, where they form metastases (5, 7).When bone metastases are established, median survival is reported to range from two to three years in breast cancer, two years in prostate cancer, and not even one year in lung cancer (8). However, it can also be substantially shorter, for example six months in melanoma, six to seven months in lung cancer or six to nine months in bladder cancer (5,(9)(10)(11)(12)(13).According to the literature, the lung, the live...